Natuzem

---

---

---

October 26, 2026

WARNING LETTER
Reference Number: 737558

To Natuzem:

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://natuzem.com, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

FDA Review

Violations were identified and documented during a review of your website https://natuzem.com/ in September 2026. Based on our review, “Testitón Extra Strong vials,” “Reumofan Plus,” and “Artrifan King” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.

Violations of the Federal Food, Drug, and Cosmetic Act

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.

Unapproved New Drug Violations

Based on a review of your website, “Testitón Extra Strong vials,” “Reumofan Plus,” and “Artrifan King” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

Testitón Extra Strong vials
On the webpage https://natuzem.com/en/products/amp-testiton-extra-fuerte-c-10-de-15-ml-herbomex:

• “Reduces premature ejaculation.”
• “It helps blood circulation, improving erection.”

Reumofan Plus
On the webpage https://natuzem.com/en/products/reumofan?keyword=reumofan:

• “Reumofan is used to treat arthritis . . . osteoarthritis, osteoporosis, bone cancer.”

Artrifan King
On the webpage https://natuzem.com/en/products/artrifan-king:

• “[S]upports cartilage regeneration, improves mobility, and provides additional protection against serious diseases such as bone cancer.”

“Testitón Extra Strong vials,” “Reumofan Plus,” and “Artrifan King” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

We also observed that your website https://natuzem.com/ offers “RMSOL Gracian,” “Kuka Flex Forte,” and “Reuma King” for sale to consumers in the United States. Previous FDA lab analyses of products similarly named to “Reumofan Plus,”¹ “Artrifan King,”² “RMSOL Gracian,”³ “Kuka Flex Forte,”⁴ and “Reuma King”⁵ sold on your website revealed these products contained undeclared drug ingredients. While the Agency has not sampled and tested these product variations from your inventory to date, this letter expresses our serious concern about the safety of these products. We emphasize that it is your legal responsibility under federal law to ensure that products you sell do not contain any undeclared or potentially harmful ingredients, and that they are marketed in compliance with applicable laws.

Conclusion

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “737558” in the subject line of the email.

Please note FDA posts warning letters on www.fda.gov.

Sincerely,
/S/

Tina Smith, M.S.
Captain, U.S. Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

________________________

1 https://www.fda.gov/drugs/medication-health-fraud/questions-and-answers-reumofan-plus-and-reumofan-plus-premium

2 https://www.fda.gov/drugs/medication-health-fraud/artrifan-king-may-be-harmful-due-hidden-drug-ingredients

3 https://www.fda.gov/drugs/medication-health-fraud/rmsol-gracian-contains-hidden-drug-ingredient

4 https://www.fda.gov/drugs/medication-health-fraud/kuka-flex-forte-contains-hidden-drug-ingredient

5 https://www.fda.gov/drugs/medication-health-fraud-notifications/reuma-king-may-be-harmful-due-hidden-drug-ingredients